MESO Mesoblast Limited
USHealthcareAs of 2026-10-08
Why MESO matters now
Mesoblast Limited (MESO) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.75 with -1.36% on the session and $1.78B in market capitalization; recent performance reads 1-month -1.24% and YTD -20.34%.
The latest financial table shown here is Q4 2025, with revenue of $7.0M, net income of $-27.1M, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.7%.
The latest indexable market news headline is "Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.50; recent insider activity includes COBLEY LYNETTE ELIZABETH filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.31
P/S
123.68
EV/EBITDA
-39.76
DCF Value
$-2.66
FCF Yield
-2.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-218.7%
Operating Margin
-572.0%
Net Margin
-500.5%
ROE
-14.0%
ROA
-10.0%
ROIC
-12.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $7.0M | $-27.1M | $-0.21 |
| FY 2025 | $17.2M | $-102.1M | $-0.84 |
| Q3 2025 | $7.0M | $-27.1M | $-0.21 |
| Q2 2025 | $1.6M | $-24.0M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.50
Target (Median)
$11.50
Target Range
$11.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
AU
Exchange
—
Beta
0.79
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.